Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Tumor ablation is a minimally invasive technique that is commonly used in the treatment of tumors of the liver, kidney, bone, and lung. It is an important option for people who have failed chemotherapy or radiotherapy or are not surgical candidates. Ablation is also being considered a potential first-line treatment in many patients with small hepatocellular carcinomas or benign tumors in the liver.
Most ablation systems comprise a generator and a needlelike device that delivers the energy directly to the targeted tissue to cause acute cellular necrosis. Radio-frequency (RF), microwave (MW), laser, and high-intensity focused ultrasound (HIFU) systems apply energy to heat the tissue to at least 60 C for maximum efficacy. Cryoablation systems cool the tissue to less than ?40°C to cause tissue necrosis. Irreversible electroporation (IRE) is an ostensibly nonthermal technique. Targeted tissues can be accessed percutaneously, laparoscopically, through a celiotomy incision, or endoscopically. A prominent exception is HIFU, which can be completed with a specialized ultrasound probe extracorporeally. Thus, tumor ablation is largely a minimally invasive technique but can also be useful as an adjuvant to surgery.
The global tumor ablation market is observing significant growth owing to increasing population base for cancer patients and rapidly growing elderly population. Increasing cases of cancer across the globe is the key growth-driving factor for this market. About 13.0% of the population suffers from cancer each year, as per the statistics by the World Health Organization (WHO).
The market is further boosted by demand for minimally invasive procedures due to the benefits, such as less trauma, speedy recovery, along with technological advancements in the field of thermal ablation. In addition, increasing per capita income is enabling people to take up advanced treatment for tumors, thus driving the growth of this market. Active role of healthcare agencies and government in creating awareness about various cancer types is also expected to facilitate usage of tumor ablation therapy, thereby supporting market development. However, the market is hindered by limited reimbursements and cost containment measures taken by various governments.
The report analyses the global tumor ablation market based on technology, treatment, application and geography.
Based on technology, the market is categorized into cryoablation, irreversible electroporation, microwave ablation, radiofrequency ablation and other ablation technologies. Radiofrequency (RF) ablation has become the method of choice because of its safety and efficacy. Image-guided RF ablation is minimally invasive and usually appropriate for inoperable patients with other comorbidities.
The tumor ablation market offers treatments in laparoscopic ablation, percutaneous ablation and surgical ablation. In the last decade, there has been a rapid advancement in the utilization of percutaneous, image-guided tumor ablation methods, and RF ablation has been the method of choice because of its availability, safety, efficacy, and cost.
Furthermore, various applications of this market are categorized into bone cancer, brain cancer, breast cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer and others. Lung cancer is the leading cause of cancer-related death in both men and women, and NSCLC accounts for most of the cases. RF ablation, alone or in combination with other treatment modalities such as external beam radiation, is an alternative option for patients and is currently the most commonly utilized thermal ablation method with promising survival data. RF ablation can also be used in patients with metastatic lung disease for eradication of small tumors.
By geography, the global tumor ablation market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in U.S. and Canada. Furthermore, Asia Pacific is expected to witness lucrative growth over the forecast period owing to supportive government initiatives and improving healthcare infrastructure. Additionally, economic developments in countries, such as India and China, are expected to help spur the market growth. Huge population base with low per capita income in the region led to high demand for affordable treatment options.
The leading tumor ablation market players are Angiodynamics, Inc., Boston Scientific Corporation, Edap Tms S.A., Galil Medical, Inc., Healthtronics, Inc., Medtronic, PLC., Mermaid Medical A/S, Misonix, Inc., Neuwave Medical, Inc. and Sonacare Medical, LLC. These companies have adopted various strategies, such as new product launches, collaborations, technological advancements, M&A, to sustain their position in the market.
The global tumor ablation market is segmented based on technology, treatment, application and geography. Based on technology, the market is categorized into cryoablation, irreversible electroporation, microwave ablation, radiofrequency ablation and other ablation technologies. Radiofrequency (RF) ablation has become the method of choice because of its safety and efficacy. Image-guided RF ablation is minimally invasive and usually appropriate for inoperable patients with other comorbidities.
The tumor ablation market offers treatments in laparoscopic ablation, percutaneous ablation and surgical ablation. In the last decade, there has been a rapid advancement in the utilization of percutaneous, image-guided tumor ablation methods, and RF ablation has been the method of choice because of its availability, safety, efficacy, and cost.
Furthermore, various applications of this market are categorized into bone cancer, brain cancer, breast cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer and others. Lung cancer is the leading cause of cancer-related death in both men and women, and NSCLC accounts for most of the cases.
By geography, the global tumor ablation market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in U.S. and Canada.
Why to buy this report:
